Tips for reducing site queries and improving workflows.
Harold Strandquist
The process of collecting cardiac safety electrocardiogram (ECG) data in clinical trials is stuck in the past. Too often, site personnel must rely on bulky ECG machines that collect results and submit them in batches, manage paper records, and perform manual data selection. All this creates roadblocks and opens the door to human error and the kinds of site queries that grind progress to a halt. This often happens because legacy core labs are heavily invested in technologies that are less than efficient when it comes to managing and sharing results. This creates a lack of integration and subsequent inefficiencies. Trial sponsors may still get the results they need, but it is often a time—and labor—intensive process for research personnel.
Fortunately, there is a better way to work. Modern technology can empower site personnel to cut errors, reduce queries, and work more efficiently. Why does that matter? Because research has repeatedly shown that happy workers are more productive. For research site personnel, that may mean they’re more likely to go the extra mile—collect more accurate data, enroll more participants, and provide better information. Here are four factors to consider as you evaluate technology and partners for your next cardiac safety trial:
Advances in ECG acquisition technology improve speed, accuracy, compliance, and data security. Working with digital data throughout the process ensures information won’t be recorded under the wrong name, or that paper records won’t be accidentally filed in the wrong place. It’s a defense against human error, in other words. In the long run, that means research sponsors can reduce queries and help research sites achieve better results, in less time, and with significantly less frustration.
Harold Strandquist, President, HeartcoR Solutions
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.